However, maximum tolerated dose regimens are associated with a loss of CD8+ and CD4+ T-cells and NK cells from the tumor microenvironment, and pro-tumoral activation of cancer-associated fibroblasts (105). The gene discussed is CD8A; the disease is cancer.